Expression and putative functions of melatonin receptors in malignant cells and tissues;Expression und mögliche Funktionen von Melatonin-Rezeptoren in humanen Karzinomzellen und im Krebsgewebe

Wiener Medizinische Wochenschrift

Volumn 164, Issue 21-22, 2014, Pages 472-478

  Ekmekcioglu, Cem ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antioxidative; Cancer; Melatonin; Melatonin receptors

Indexed keywords

MELATONIN; MELATONIN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER TISSUE; COLORECTAL CANCER; HUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CANCER; APOPTOSIS; CELL MEMBRANE; CELL PROLIFERATION; CELL TRANSFORMATION; GENE EXPRESSION; GENETICS; PHYSIOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; CELL MEMBRANE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; HUMANS; RECEPTORS, MELATONIN; TUMOR CELLS, CULTURED;

EID: 84920998002     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-014-0289-6     Document Type: Article

References (108)

1. Lerner AB, Case JD, Takahashi Y, et al. Isolation of melatonin, a pineal factor that lightens melanocytes. J Am Chem Soc. 1958;80:2057–8.
2. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24.
3. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, et al. Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol Cell Endocrinol. 2012;351:152–66.
4. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine reviews. 1991;12:151–80.
5. Allegra M, Reiter RJ, Tan DX, et al. The chemistry of melatonin’s interaction with reactive species. J Pineal Res. 2003;34:1–10.
6. Tan DX, Manchester LC, Hardeland R, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res. 2003;34:75–8.
7. Pandi-Perumal SR, BaHammam AS, Brown GM, et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res. 2013;23:267–300.
8. Benitez-King G, Anton-Tay F. Calmodulin mediates melatonin cytoskeletal effects. Experientia. 1993;49:635–41.
9. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, et al. Involvement of nuclear binding sites for melatonin in the regulation of il-2 and il-6 production by human blood mononuclear cells. J Neuroimmunol. 1998;92:76–84.
10. Steinhilber D, Brungs M, Werz O, et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human b lymphocytes. J Biol Chem. 1995;270:7037–40.
11. Dubocovich ML, Delagrange P, Krause DN, et al. International union of basic and clinical pharmacology. Lxxv. Nomenclature, classification, and pharmacology of g protein-coupled melatonin receptors. Pharmacol Rev. 2010;62:343–80.
12. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, et al. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. 2003;8:d1093–108.
13. Barrett P, Conway S, Morgan PJ. Digging deep–structure-function relationships in the melatonin receptor family. J Pineal Res. 2003;35:221–30.
14. New DC, Tsim ST, Wong YH. G protein-linked effector and second messenger systems involved in melatonin signal transduction. Neurosignals. 2003;12:59–70.
15. Masana MI, Dubocovich ML. Melatonin receptor signaling: finding the path through the dark. Sci STKE. 2001;2001:PE39.
16. Jiang ZG, Nelson CS, Allen CN. Melatonin activates an outward current and inhibits ih in rat suprachiasmatic nucleus neurons. Brain Res. 1995;687:125–32.
17. Ben Soussia I, Mies F, Naeije R, et al. Melatonin down-regulates volume-sensitive chloride channels in fibroblasts. Pflugers Arch. 2012;464:273–85.
18. Reppert SM, Godson C, Mahle CD, et al. Molecular characterization of a second melatonin receptor expressed in human retina and brain: The mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995;92:8734–8.
19. Petit L, Lacroix I, de Coppet P, et al. Differential signaling of human mel1a and mel1b melatonin receptors through the cyclic guanosine 3′-5′-monophosphate pathway. Biochem Pharmacol. 1999;58:633–9.
20. Hunt AE, Al-Ghoul WM, Gillette MU, et al. Activation of mt(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol. 2001;280:C110–8.
21. Ayoub MA, Couturier C, Lucas-Meunier E, et al. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem. 2002;277:21522–8.
22. Mailliet F, Ferry G, Vella F, et al. Organs from mice deleted for nrh:Quinone oxidoreductase 2 are deprived of the melatonin binding site mt3. FEBS Lett. 2004;578:116–20.
23. Nosjean O, Ferro M, Coge F, et al. Identification of the melatonin-binding site mt3 as the quinone reductase 2. J Biol Chem. 2000;275:31311–7.
24. Pintor J, Pelaez T, Hoyle CH, et al. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: Further evidence for an mt3 receptor. Br J Pharmacol. 2003;138:831–6.
25. Reppert SM, Weaver DR, Ebisawa T, et al. Cloning of a melatonin-related receptor from human pituitary. FEBS Lett. 1996;386:219–24.
26. von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002;309:151–62.
27. Witt-Enderby PA, Bennett J, Jarzynka MJ, et al. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci. 2003;72:2183–98.
28. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother. 2006;60:97–108.
29. Weaver DR, Reppert SM. The mel1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport. 1996;8:109–12.
30. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–49.
31. Okamura H, Doi M, Fustin JM, et al. Mammalian circadian clock system: molecular mechanisms for pharmaceutical and medical sciences. Adv Drug Deliv Rev. 2010;62:876–84.
32. Imbesi M, Arslan AD, Yildiz S, et al. The melatonin receptor mt1 is required for the differential regulatory actions of melatonin on neuronal ‘clock’ gene expression in striatal neurons in vitro. J Pineal Res. 2009;46:87–94.
33. Nemeth C, Humpeler S, Kallay E, et al. Decreased expression of the melatonin receptor 1 in human colorectal adenocarcinomas. J Biol Regul Homeost Agents. 2011;25:531–42.
34. Arendt J, Skene DJ, Middleton B, et al. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms. 1997;12:604–17.
35. Spadoni G, Bedini A, Rivara S, et al. Melatonin receptor agonists: New options for insomnia and depression treatment. CNS Neurosci Ther. 2011;17:733–41.
36. Zhdanova IV. Melatonin as a hypnotic: Pro. Sleep Med Rev. 2005;9:51–65.
37. Uchikawa O, Fukatsu K, Tokunoh R, et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem. 2002;45:4222–39.
38. Wu YH, Ursinus J, Zhou JN, et al. Alterations of melatonin receptors mt1 and mt2 in the hypothalamic suprachiasmatic nucleus during depression. J Affect Disord. 2013;148:357–67.
39. Hickie IB, Rogers NL. Novel melatonin-based therapies: Potential advances in the treatment of major depression. Lancet. 2011;378:621–31.
40. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (s20098) is an antagonist at 5-hydroxytryptamine 2c receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954–64.
41. Savaskan E, Olivieri G, Meier F, et al. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of alzheimer’s disease patients. J Pineal Res. 2002;32:59–62.
42. Uz T, Arslan AD, Kurtuncu M, et al. The regional and cellular expression profile of the melatonin receptor mt1 in the central dopaminergic system. Brain Res Mol Brain Res. 2005;136:45–53.
43. Scher J, Wankiewicz E, Brown GM, et al. Mt(1) melatonin receptor in the human retina: Expression and localization. Invest Ophthalmol Vis Sci. 2002;43:889–97.
44. Ekmekcioglu C, Haslmayer P, Philipp C, et al. 24h variation in the expression of the mt1 melatonin receptor subtype in coronary arteries derived from patients with coronary heart disease. Chronobiol Int. 2001;18:973–85.
45. Ekmekcioglu C, Haslmayer P, Philipp C, et al. Expression of the mt1 melatonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res. 2001;21:85–91.
46. Ekmekcioglu C, Thalhammer T, Humpeler S, et al. The melatonin receptor subtype mt2 is present in the human cardiovascular system. J Pineal Res 2003;35:40–4.
47. Aust S, Thalhammer T, Humpeler S, et al. The melatonin receptor subtype mt1 is expressed in human gallbladder epithelia. J Pineal Res. 2004;36:43–8.
48. Toma CD, Svoboda M, Arrich F, et al. Expression of the melatonin receptor (mt) 1 in benign and malignant human bone tumors. J Pineal Res. 2007;43:206–13.
49. Rogelsperger O, Wlcek K, Ekmekcioglu C, et al. Melatonin receptors, melatonin metabolizing enzymes and cyclin d1 in human breast cancer. J Recept Signal Transduct Res. 2011;31:180–7.
50. Rogelsperger O, Ekmekcioglu C, Jager W, et al. Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J Pineal Res. 2009;46:422–32.
51. Yang Q, Scalbert E, Delagrange P, et al. Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries. Am J Physiol Heart Circ Physiol. 2001;280:H76–82.
52. Masana MI, Doolen S, Ersahin C, et al. Mt(2) melatonin receptors are present and functional in rat caudal artery. J Pharmacol Exp Ther. 2002;302:1295–302.
53. Krauchi K, Cajochen C, Wirz-Justice A. A relationship between heat loss and sleepiness: Effects of postural change and melatonin administration. J Appl Physiol. 1997;83:134–9.
54. van den Heuvel CJ, Kennaway DJ, Dawson D. Thermoregulatory and soporific effects of very low dose melatonin injection. Am J Physiol. 1999;276:E249–54.
55. Cook JS, Sauder CL, Ray CA. Melatonin differentially affects vascular blood flow in humans. Am J Physiol Heart Circ Physiol. 2011;300:H670–4.
56. Arangino S, Cagnacci A, Angiolucci M, et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol. 1999;83:1417–9.
57. Raikhlin NT, Kvetnoy IM, Tolkachev VN. Melatonin may be synthesised in enterochromaffin cells. Nature. 1975;255:344–5.
58. Sjoblom M, Jedstedt G, Flemstrom G. Peripheral melatonin mediates neural stimulation of duodenal mucosal bicarbonate secretion. J Clin Invest. 2001;108:625–33.
59. Le Gouic S, Delagrange, Atgie C, et al. Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the garden dormouse. Int J Obes Relat Metab Disord. 1996;20:661–7.
60. Viswanathan M, Hissa R, George JC. Effects of short photoperiod and melatonin treatment on thermogenesis in the syrian hamster. J Pineal Res. 1986;3:311–21.
61. Kozirog M, Poliwczak AR, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011;50:261–6.
62. Peschke E, Bahr I, Muhlbauer E. Melatonin and pancreatic islets: Interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14:6981–7015.
63. Peschke E, Schucht H, Muhlbauer E. Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both wistar and type 2-diabetic goto-kakizaki rats. J Pineal Res. 2010;49:373–81.
64. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, et al. A variant near mtnr1b is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41:89–94.
65. Chambers JC, Zhang W, Zabaneh D, et al. Common genetic variation near melatonin receptor mtnr1b contributes to raised plasma glucose and increased risk of type 2 diabetes among indian asians and european caucasians. Diabetes. 2009;58:2703–8.
66. Xia Q, Chen ZX, Wang YC, et al. Association between the melatonin receptor 1b gene polymorphism on the risk of type 2 diabetes, impaired glucose regulation: a meta-analysis. PLoS One. 2012;7:e50107.
67. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, et al. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem. 2010;17:4462–81.
68. Cutando A, Lopez-Valverde A, Arias-Santiago S, et al. Role of melatonin in cancer treatment. Anticancer Res. 2012;32:2747–53.
69. Cohen M, Lippman M, Chabner B. Pineal gland and breast cancer. Lancet. 1978;2:1381–2.
70. Bartsch C, Bartsch H, Jain AK, et al. Urinary melatonin levels in human breast cancer patients. J Neural Transm. 1981;52:281–94.
71. Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. 2013;17:273–84.
72. Hansen J, Lassen CF. Nested case-control study of night shift work and breast cancer risk among women in the danish military. Occup Environ Med. 2012;69:551–6.
73. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2008;100:898–905.
74. Proietti S, Cucina A, Reiter RJ, et al. Molecular mechanisms of melatonin’s inhibitory actions on breast cancers. Cell Mol Life Sci. 2013;70:2139–57.
75. Yuan L, Collins AR, Dai J, et al. Mt(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol. 2002;192:147–56.
76. Dillon DC, Easley SE, Asch BB, et al. Differential expression of high-affinity melatonin receptors (mt1) in normal and malignant human breast tissue. Am J Clin Pathol. 2002;118:451–8.
77. Garcia Pedrero JM, Del Rio, Martinez-Campa C, et al. Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol. 2002;16:947–60.
78. Cos S, Gonzalez A, Martinez-Campa C, et al. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 2006;30:118–28.
79. Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21waf1 expression in mcf-7 human breast cancer cells in vitro. Life Sci. 1999;65:415–20.
80. Santoro R, Mori F, Marani M, et al. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. Carcinogenesis. 2013;34:1051–61.
81. Cos S, Blask DE, Lemus-Wilson A, et al. Effects of melatonin on the cell cycle kinetics and “estrogen-rescue” of mcf-7 human breast cancer cells in culture. J Pineal Res. 1991;10:36–42.
82. Kauppila A, Kivela A, Pakarinen A, et al. Inverse seasonal relationship between melatonin and ovarian activity in humans in a region with a strong seasonal contrast in luminosity. J Clin Endocrinol Metab. 1987;65:823–8.
83. Hill SM, Blask DE, Xiang S, et al. Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J Mammary Gland Biol Neoplasia. 2011;16:235–45.
84. Jablonska K, Pula B, Zemla A, et al. Expression of melatonin receptor mt1 in cells of human invasive ductal breast carcinoma. J Pineal Res. 2013;54:334–45.
85. Oprea-Ilies G, Haus E, Sackett-Lundeen L, et al. Expression of melatonin receptors in triple negative breast cancer (tnbc) in african american and caucasian women: relation to survival. Breast Cancer Res Treat. 2013;137:677–87.
86. GLOBOCAN: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.Iarc.fr. Accessed 7 July 2014
87. Shiu SY. Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. J Pineal Res. 2007;43:1–9.
88. Joo SS, Yoo YM. Melatonin induces apoptotic death in lncap cells via p38 and jnk pathways: therapeutic implications for prostate cancer. J Pineal Res. 2009;47:8–14.
89. Jung-Hynes B, Schmit TL, Reagan-Shaw SR, et al. Melatonin, a novel sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in tramp model. J Pineal Res. 2011;50:140–9.
90. Xi SC, Tam PC, Brown GM, et al. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive lncap human prostate cancer cells. J Pineal Res. 2000;29:172–83.
91. Tam CW, Chan KW, Liu VW, et al. Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. J Pineal Res. 2008;45:403–12.
92. Gilad E, Laudon M, Matzkin H, et al. Functional melatonin receptors in human prostate epithelial cells. Endocrinology. 1996;137:1412–7.
93. Laudon M, Gilad E, Matzkin H, et al. Putative melatonin receptors in benign human prostate tissue. J Clin Endocrinol Metab. 1996;81:1336–42.
94. Tam CW, Shiu SY. Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer. J Pineal Res. 2011;51:297–312.
95. Tam CW, Mo CW, Yao KM, et al. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res. 2007;42:191–202.
96. Fernandez PL, Arce Y, Farre X, et al. Expression of p27/kip1 is down-regulated in human prostate carcinoma progression. J Pathol. 1999;187:563–6.
97. Rimler A, Culig Z, Levy-Rimler G, et al. Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. The Prostate. 2001;49:145–54.
98. Kos-Kudla B, Ostrowska Z, Kozlowski A, et al. Circadian rhythm of melatonin in patients with colorectal carcinoma. Neuro Endocrinol Lett. 2002;23:239–42.
99. Schernhammer ES, Laden F, Speizer FE, et al. Night-shift work and risk of colorectal cancer in the nurses’ health study. J Natl Cancer Inst. 2003;95:825–8.
100. Farriol M, Venereo Y, Orta X, et al. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol. 2000;20:21–4.
101. Slominski A, Pisarchik A, Semak I, et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. Faseb J. 2002;16:896–8.
102. Slominski A, Pisarchik A, Zbytek B, et al. Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol. 2003;196:144–53.
103. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: Securing a place under the sun. Faseb J. 2005;19:176–94.
104. Hu DN, Roberts JE. Melatonin inhibits growth of cultured human uveal melanoma cells. Melanoma Res. 1997;7:27–31.
105. Ying SW, Niles LP, Crocker C. Human malignant melanoma cells express high-affinity receptors for melatonin: Antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol. 1993;246:89–96.
106. Cabrera J, Negrin G, Estevez F, et al. Melatonin decreases cell proliferation and induces melanogenesis in human melanoma sk-mel-1 cells. J Pineal Res. 2010;49:45–54.
107. Danielczyk K, Dziegiel P. The expression of mt1 melatonin receptor and ki-67 antigen in melanoma malignum. Anticancer Res. 2009;29:3887–95.
108. Kleszczynski K, Fischer TW. Melatonin and human skin aging. Dermatoendocrinol. 2012;4:245–52.